Burden of symptoms could guide NSCLC pemetrexed use

Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news